Edap Tms (NASDAQ:EDAP) Director Buys $42,200.00 in Stock

Edap Tms S.A. (NASDAQ:EDAP) Director Joshua Levine acquired 10,000 shares of Edap Tms stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $4.22 per share, for a total transaction of $42,200.00. Following the completion of the acquisition, the director directly owned 35,000 shares in the company, valued at approximately $147,700. This represents a 40.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Edap Tms Price Performance

Shares of EDAP opened at $4.08 on Wednesday. Edap Tms S.A. has a twelve month low of $1.21 and a twelve month high of $5.05. The firm’s fifty day simple moving average is $3.70 and its 200-day simple moving average is $3.41. The firm has a market capitalization of $152.92 million, a price-to-earnings ratio of -5.04 and a beta of -0.10. The company has a current ratio of 1.34, a quick ratio of 0.99 and a debt-to-equity ratio of 1.79.

Edap Tms (NASDAQ:EDAP) last posted its earnings results on Thursday, May 7th. The medical equipment provider reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $20.48 million during the quarter, compared to analysts’ expectations of $19.46 million. Edap Tms had a negative net margin of 41.47% and a negative return on equity of 137.61%. Equities analysts forecast that Edap Tms S.A. will post -0.82 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on EDAP. HC Wainwright reduced their target price on shares of Edap Tms from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Wall Street Zen cut shares of Edap Tms from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Edap Tms currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Institutional Trading of Edap Tms

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Financial Planning Navigators CORP acquired a new stake in shares of Edap Tms in the fourth quarter valued at about $33,000. SmartHarvest Portfolios LLC acquired a new position in Edap Tms during the first quarter worth about $38,000. Kovack Advisors Inc. purchased a new stake in shares of Edap Tms during the fourth quarter worth about $53,000. Rock Springs Capital Management LP grew its holdings in shares of Edap Tms by 1.3% during the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider’s stock worth $4,233,000 after buying an additional 16,500 shares in the last quarter. Finally, Leonteq Securities AG purchased a new stake in shares of Edap Tms during the fourth quarter worth about $313,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

Edap Tms Company Profile

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.